RL 315535

Drug Profile

RL 315535

Alternative Names: LY 315535

Latest Information Update: 21 Jun 2000

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Unknown
  • Developer Shire Pharmaceuticals Group
  • Class Irritable bowel syndrome therapies
  • Mechanism of Action Muscarinic receptor antagonists; Serotonin 1A receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Irritable bowel syndrome; Non-ulcer dyspepsia

Most Recent Events

  • 21 Jun 2000 RL 315535 is available for licensing (http://www.shire.com)
  • 27 Mar 2000 Discontinued-I for Irritable bowel syndrome in USA (PO)
  • 27 Mar 2000 Discontinued-I for Non-ulcer dyspepsia in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top